Nikko Asset Management Americas Inc. Sells 2,730 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Nikko Asset Management Americas Inc. trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 9.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,154 shares of the biopharmaceutical company's stock after selling 2,730 shares during the period. Nikko Asset Management Americas Inc.'s holdings in Regeneron Pharmaceuticals were worth $18,630,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. Howe & Rusling Inc. boosted its stake in Regeneron Pharmaceuticals by 3.4% in the 3rd quarter. Howe & Rusling Inc. now owns 462 shares of the biopharmaceutical company's stock worth $486,000 after purchasing an additional 15 shares during the period. Willner & Heller LLC boosted its position in shares of Regeneron Pharmaceuticals by 3.9% during the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company's stock worth $284,000 after acquiring an additional 15 shares during the last quarter. OLD Second National Bank of Aurora grew its stake in Regeneron Pharmaceuticals by 0.5% during the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock valued at $2,025,000 after acquiring an additional 15 shares in the last quarter. Rakuten Securities Inc. increased its holdings in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 15 shares during the last quarter. Finally, GLOBALT Investments LLC GA increased its holdings in Regeneron Pharmaceuticals by 1.5% in the 3rd quarter. GLOBALT Investments LLC GA now owns 1,067 shares of the biopharmaceutical company's stock valued at $1,122,000 after acquiring an additional 16 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on REGN shares. TD Cowen cut their price objective on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research report on Tuesday, February 4th. Leerink Partnrs raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating for the company in a research report on Wednesday, January 8th. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, December 17th. Finally, Piper Sandler lowered their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a research report on Monday, January 27th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $973.13.

Regeneron Pharmaceuticals Stock Down 0.6 %

Shares of REGN stock traded down $4.14 on Friday, hitting $658.48. The stock had a trading volume of 1,869,108 shares, compared to its average volume of 632,994. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20. The business has a 50 day moving average price of $690.20 and a 200 day moving average price of $821.82. The company has a market cap of $71.99 billion, a PE ratio of 17.20, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the previous year, the business posted $11.86 EPS. The company's quarterly revenue was up 10.3% compared to the same quarter last year. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.53%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.